Engler JR - Search Results

1

Measuring Sulfatase Expression and Invasion in Glioblastoma.

Wade A, Engler JR, Tran VM, Phillips JJ. Wade A, et al. Among authors: engler jr. Methods Mol Biol. 2022;2303:415-425. doi: 10.1007/978-1-0716-1398-6_33. Methods Mol Biol. 2022. PMID: 34626397

2

Proteoglycans and their roles in brain cancer.

Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Phillips JJ. Wade A, et al. Among authors: engler jr. FEBS J. 2013 May;280(10):2399-417. doi: 10.1111/febs.12109. Epub 2013 Feb 6. FEBS J. 2013. PMID: 23281850 Free PMC article. Review.

3

Measuring sulfatase expression and invasion in glioblastoma.

Wade A, Engler JR, Tran VM, Phillips JJ. Wade A, et al. Among authors: engler jr. Methods Mol Biol. 2015;1229:507-16. doi: 10.1007/978-1-4939-1714-3_39. Methods Mol Biol. 2015. PMID: 25325976 Free PMC article.

4

Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Tran VM, Wade A, McKinney A, Chen K, Lindberg OR, Engler JR, Persson AI, Phillips JJ. Tran VM, et al. Among authors: engler jr. Mol Cancer Res. 2017 Nov;15(11):1623-1633. doi: 10.1158/1541-7786.MCR-17-0352. Epub 2017 Aug 4. Mol Cancer Res. 2017. PMID: 28778876 Free PMC article.

5

Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.

Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ. Engler JR, et al. PLoS One. 2012;7(8):e43339. doi: 10.1371/journal.pone.0043339. Epub 2012 Aug 22. PLoS One. 2012. PMID: 22937035 Free PMC article.

6

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.

Lindberg OR, McKinney A, Engler JR, Koshkakaryan G, Gong H, Robinson AE, Ewald AJ, Huillard E, David James C, Molinaro AM, Shieh JT, Phillips JJ. Lindberg OR, et al. Among authors: engler jr. Oncotarget. 2016 Nov 29;7(48):79101-79116. doi: 10.18632/oncotarget.12600. Oncotarget. 2016. PMID: 27738329 Free PMC article.

7

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ. McKinney A, et al. Among authors: engler jr. Mol Cancer Ther. 2019 Sep;18(9):1565-1576. doi: 10.1158/1535-7163.MCT-18-1330. Epub 2019 Jul 3. Mol Cancer Ther. 2019. PMID: 31270152 Free PMC article.

8

OCT-1 as a determinant of response to antileukemic treatment.

Engler JR, Hughes TP, White DL. Engler JR, et al. Clin Pharmacol Ther. 2011 Apr;89(4):608-11. doi: 10.1038/clpt.2011.12. Epub 2011 Feb 23. Clin Pharmacol Ther. 2011. PMID: 21346750 No abstract available.

9

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.

Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. Engler JR, et al. Blood. 2010 Oct 14;116(15):2776-8. doi: 10.1182/blood-2010-01-267013. Epub 2010 Jul 15. Blood. 2010. PMID: 20634379 Free article.

10

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. White DL, et al. Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30. Blood. 2007. PMID: 17761829 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters